Research Article

COX-2/sEH Dual Inhibitor PTUPB Attenuates Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells via Nrf2-Mediated Inhibition of TGF-β1/Smad Signaling

Chen-Yu Zhang,1,2 Xin-Xin Guan,1 Zhuo-Hui Song,3 Hui-Ling Jiang,1 Yu-Biao Liu,1 Ping Chen,2,4 Jia-Xi Duan,2,4 and Yong Zhou1

1Department of Physiology, School of Basic Medicine Science, Central South University, Changsha, Hunan 410078, China
2Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410078, China
3Department of Physiology, Changzhi Medical College, Changzhi, Shanxi 046000, China
4Research Unit of Respiratory Disease, Central South University, Changsha, Hunan 410011, China

Correspondence should be addressed to Jia-Xi Duan; duancrystal@126.com and Yong Zhou; zhouyong421@csu.edu.cn

Received 18 December 2021; Revised 2 April 2022; Accepted 9 April 2022; Published 25 April 2022

Academic Editor: Alessandro Poggi

Copyright © 2022 Chen-Yu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Arachidonic acid (ARA) metabolites are involved in the pathogenesis of epithelial-mesenchymal transformation (EMT). However, the role of ARA metabolism in the progression of EMT during pulmonary fibrosis (PF) has not been fully elucidated. The purpose of this study was to investigate the role of cytochrome P450 oxidase (CYP)/soluble epoxide hydrolase (sEH) and cyclooxygenase-2 (COX-2) metabolic disorders of ARA in EMT during PF.

Methods. A signal intratracheal injection of bleomycin (BLM) was given to induce PF in C57BL/6 J mice. A COX-2/sEH dual inhibitor PTUPB was used to establish the function of CYPs/COX-2 dysregulation to EMT in PF mice.

In vitro experiments, murine alveolar epithelial cells (MLE12) and human alveolar epithelial cells (A549) were used to explore the roles and mechanisms of PTUPB on transforming growth factor (TGF)-β1-induced EMT.

Results. PTUPB treatment reversed the increase of mesenchymal marker molecule α-smooth muscle actin (α-SMA) and the loss of epithelial marker molecule E-cadherin in lung tissue of PF mice. In vitro experiments, murine alveolar epithelial cells (MLE12) and human alveolar epithelial cells (A549) were used to explore the roles and mechanisms of PTUPB on transforming growth factor (TGF)-β1-induced EMT. PTUPB treatment reversed the increase of mesenchymal marker molecule α-SMA and the loss of epithelial marker molecule E-cadherin in lung tissue of PF mice. In vitro, COX-2 and sEH protein levels were increased in TGF-β1-treated alveolar epithelial cells (AECs). PTUPB decreased the expression of α-SMA and restored the expression of E-cadherin in TGF-β1-treated AECs, accompanied by reduced migration and collagen synthesis. Moreover, PTUPB attenuated TGF-β1-Smad2/3 pathway activation in AECs via Nrf2 antioxidant cascade.

Conclusion. PTUPB inhibits EMT in AECs via Nrf2-mediated inhibition of the TGF-β1-Smad2/3 pathway, which holds great promise for the clinical treatment of PF.

1. Introduction

Pulmonary fibrosis (PF) is a prototype of chronic, progressive, and fibrotic lung disease. An altered extracellular matrix replaces healthy tissue, and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death [1]. Although pirfenidone and nintedanib have been authorized by the Food and Drug Administration [2], they only slow down lung function decline in patients with the mild and moderate disease [3]. Therefore, it is urgent to develop an effective treatment for PF.

Epithelial-mesenchymal transition (EMT) is a reversible process in which epithelial cells lose their cellular polarity and obtain migration characteristics through down-regulation of E-cadherin-mediated cell adhesion [4]. EMT is involved in wound healing, fibrosis, embryonic development, and cancer metastasis [5]. Most investigators concur that alveolar type II epithelial cells undergo EMT during PF development [6, 7]. Studies have shown that pulmonary...
fibroblasts are derived from various routes, of which about one-third are derived from alveolar type II epithelial cells via EMT [8]. Transforming growth factor (TGF)-β1 is the most studied and is a key EMT inducer [9]. TGF-β1 activates its downstream Smad signaling pathway and plays an important role in fibrosis [10]. TGF-β1 binds to its receptor to trigger intracellular signaling and phosphorylates Smad2 and Smad3. Phosphorylated Smad2 and Smad3 are transported to the nucleus and regulate the transcription of target genes [11]. Consequently, blocking the EMT of alveolar epithelial cells (AECs) might be a promising strategy for the treatment of PF.

Oxidative stress accelerates TGF-β1-mediated fiber formation by increasing hydrogen peroxide levels, protein damage, DNA degradation, and lipid peroxidation [12]. The transcription factor nuclear factor erythroid 2-related factor-2 (Nrf2) plays an important role in intracellular anti-oxidant responses. Activated Nrf2 is transported to the nucleus and regulate the transcription of antioxidant enzymes [13]. Nrf2 balances not only oxidative stress but also has negative effects on TGF-β1-mediated profibrotic signal transduction [14, 15]. Previous studies have shown that Nrf2 plays an important role in preventing lung inflammation and fibrosis [16, 17]. These results indicate that strategies targeting Nrf2 have antipulmonary fibrosis potential.

Epoxycicosatrienoic acids (EETs), leukotrienes (LTs), and prostaglandins (PGs) are derived from arachidonic acid (ARA) with cytochrome P450 oxidase (CYP), lipoxygenase (LOX), and cyclooxygenase (COX) pathways, respectively [18]. ARA metabolites play multiple roles in almost diseases. Our previous study suggested that the expressions of h-Snail1 and Zinc-finger E-box binding (ZEB) expression are significantly attenuated murine PF [28]. We have reported that blockade of EETs degradation attenuates renal Snail1 and Zinc-finger E-box binding (ZEB) expression [29]. However, EETs are rapidly metabolized by soluble epoxide hydrolase (sEH) [24].

Our previous study suggested that the expressions of sEH and COX-2 are significantly increased in the lungs of PF mice induced by bleomycin (BLM) [30]. A compound that concurrently inhibits both COX-2 and sEH is called 4-(5-phenyl-3-[3-(4-trifluoromethylphenyl)-ureido]-propyl)-pyrazol-1-yl)-benzenesulfonamide (PTUPB), which prevents the release of PGs and increases the blood levels of EETs [31]. PTUPB is more potent in suppressing inflammatory pain and tumor growth than celecoxib, t-AUCB (an inhibitor of sEH), or the combination of celecoxib and t-AUCB [31, 32]. We have shown that PTUPB can alleviate acute lung injury [33], nonalcoholic fatty liver disease [34], and sepsis [35] in mice. What is more, we have found that PTUPB significantly attenuates BLM-induced PF in mice [30]. However, it is not clear whether PTUPB can inhibit EMT. Therefore, the present study aimed to investigate the effects of PTUPB on TGF-β1-mediated pulmonary EMT.

### 2. Materials and Methods

#### 2.1. Animal.** C57BL/6J mice (adult male, 6-8 weeks) were obtained from Hunan SJA Laboratory Animal Co., Ltd. (Hunan, China). Mice were placed in specific pathogen-free conditions for a 12h day-night cycle. Mice have free access to food and water.**
Figure 1: Continued.
2.2. Murine Model of PF and Treatment. Mice were randomly divided into the control group, PTUPB group, BLM group, and BLM+PTUPB group. For PF induction, mice received an intratracheal injection of BLM (1.5 mg/kg; Nippon Kayaku, Tokyo, Japan) dissolved in 50 μL saline. At the same time, mice in the control and PTUPB groups received 50 μL saline intratracheally. Mice in the PTUPB group and BLM+PTUPB group were subcutaneously injected with PTUPB (5 mg/kg/d) dissolved in PEG400 from day 7 to day 21 after BLM injection. PTUPB was given by Bruce D. Hammock at UC Davis Comprehensive Cancer Center, University of California [31]. PEG400 was subcutaneously injected for the control and BLM groups. Twenty-one days after the BLM injection, the mice were sacrificed. All surgeries were performed under anesthesia.

2.3. Pulmonary Histopathology Analysis. The left lung tissue was placed in a tube filled with 4% paraformaldehyde (Servicio, Wuhan, China, G1101), followed by conventional paraffin embedding. Paraffin-embedded sections were made. Hematoxylin-eosin staining (HE) was used to observe the morphological changes in lung tissue of mice, and Masson staining was used to observe the collagen deposition. The pictures were detected by a microscope (Motic, BA410E, Motic China group Co., Ltd., China) equipped with Motic images plus 3.0 (Motic, Motic China group Co., Ltd., China). The image was magnified at 200 ×, with a resolution of 683 × 705, horizontal and vertical resolutions of 96dpi, and a bit depth of 24.

2.4. Immunofluorescent Staining. The lung tissue sections were dewaxed and hydrated. EDTA buffer was used for anti- gen repair under high temperature and pressure conditions. 3% H2O2 was dropped on the sample for 10 min to achieve the purpose of removing endogenous peroxidase (the cells were washed with PBS three times and fixed with 4% paraformaldehyde for 15 minutes). After washing with PBS three times, the cells were permeated with 0.3% Triton X-100 for 15 minutes. The sections or cells were incubated in 5% albumin bovine V (BSA; Solarbio, Beijing, China, A8020) for 30 min and then incubated with α-SMA antibody (1:200; Abcam, Cambridge, MA, USA), E-cadherin antibody (1:200; Cell Signaling Technology, USA), Smad2 antibody (1:200; CST), Smad3 antibody (1:200; Abcam), or Nrf2 antibody (1:300; CST) in 5% BSA overnight at 4°C. The next day, tissue sections were rewarmed at 37°C for half an hour and then incubated with a FITC-conjugated goat antirabbit antibody (1:2000; Abcam). The nuclei were counterstained with DAPI (Invitrogen, Carlsbad, CA, USA). The coverslips were mounted in 90% glycerol in PBS. The fluorescence was detected by a fluorescence microscope (Motic, BA410E, Motic China group Co., Ltd., China) equipped with Motic images plus 3.0 (Motic, Motic China group Co., Ltd., China). The same field was photographed for green fluorescence (EX: AT480/30 ×, BS: AT505DC, EM: AT515lp) and DAPI (EX: AT375/28 ×, BS: AT415DC, EM: AT460/50 m), and then, the fields were superimposed using Image J software. The image was magnified at 200 ×, with a resolution of 1920 × 1440, horizontal and vertical resolution of 72 dpi, and a bit depth of 24.

2.5. Cell Culture and Treatment. Cells were cultured in an incubator at 37°C with 5% CO2. The A549 and MLE12 cell lines were purchased from ATCC. The immortalized human

**Figure 1:** PTUPB reduces pulmonary fibrosis in mice induced by BLM. Mice received an intratracheal injection of BLM (1.5 mg/kg). Twenty-one days later, HE and Masson staining were employed to evaluate the pulmonary morphology changes and collagen disposition ((a) HE staining: bar =50 μm; Masson staining: bar =100 μm). The Collagen I protein expression was detected by western blotting ((b–c) n = 6). The mRNA expressions of Timp1, Acta2, and Cdh1 were detected by real-time PCR ((d–f) n = 5–6). The deposition of α-SMA and E-cadherin was detected by immunofluorescence ((g) bar =100 μm). Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pairwise comparisons. *P < 0.05, ***P < 0.001, and ****P < 0.001.
alveolar epithelial cells A549 were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% bovine calf serum (Sigma-Aldrich, St. Louis, MO, USA). Murine alveolar epithelial cells MLE-12 cells were cultured in DMEM F-12 (Gibco) supplemented with 2% bovine calf serum (Sigma-Aldrich), 1% penicillin and streptomycin (Solarbio), 1% 100× ITS-G (insulin-transferrin-selenium, Solarbio), 10 nM hydrocortisone (Solarbio), and 10 nM β-estradiol (Solarbio).

To estimate the effect of PTUPB on TGF-β1 (10 ng/mL)-challenged AECs, a series of concentrations of PTUPB (0.1, 1, and 10 μM) were added 1 h before TGF-β1 stimulation.

**Figure 2:** COX-2 and sEH expression are increased in TGF-β1-treated AECs. COX-2 and sEH protein expressions in A549 cells (a–c) and MLE12 cells (d–f) were detected using western blot (n = 3). The data shown are from a representative experiment with biological triplicates. Data are expressed as the mean ± SD. Differences between the two groups were determined by an unpaired t-test. *P < 0.05.

(Solarbio), 1% 100× ITS-G (insulin-transferrin-selenium, Solarbio), 10 nM hydrocortisone (Solarbio), and 10 nM β-estradiol (Solarbio).
Figure 3: Continued.
To evaluate the role of Nrf2 in PTUPB-inhibited EMT, ML385 (Cat. No.: HY-100523, MCE) was added to inhibit Nrf2 1 h before the TGF-β1 stimulation.

2.6. Scratch Wound Healing Assay. A549 cells were cultured in 12-well plates with 2% bovine calf serum. Assigned areas of the cell surface were scratched with a 200-μL tip and washed with phosphate buffer solution three times [36]. Cells were pretreated with PTUPB (1 μM) for 1 h, followed by TGF-β1 (10 ng/mL; Novus Biologicals, Littleton, CO, USA). After 48 h of TGF-β1 treatment, the ability of cells to migrate to the scratch area was assessed by measuring the width of the scratch and calculating the difference from the initial width. Photographs were taken with a microscope (Nikon).

2.7. Cell Proliferation Assay. A549 cells were cultured in 96-well plates with 2% bovine calf serum. Cells were pretreated with PTUPB (1 μM) for 1 h, followed by TGF-β1 (10 ng/mL). After TGF-β1 treatment for 48 h, 10 μL Cell Counting Kit-8 solution (CCK-8, Dojindo Laboratories, Japan) was added to each well and incubated at 37°C for 1-3 h. The results were detected at 450 nm with a microplate analyzer (Thermo Fisher Scientific, Waltham, MA, USA).

2.8. Detection of ROS. ROS in the cells was assessed by kits following the manufacturer’s instructions (Cat# ROS: E004, Jiancheng Bioengineering Institute, Nanjing, China).

2.9. The Quantitative Real-Time PCR Analysis. Total RNA from right middle lung tissue or cells was extracted with RNAiso Plus (Takara, Kusatsu, Japan). Total RNA (1 μg) was reverse transcribed using PrimeScript RT reagent Kit (Takara). Real-time PCR was carried out to detect mRNA expression levels as described in our previous study [37]. Relative expression of genes was computed by the 2-ΔΔCT method according to our previous study [38]. The sequence of primers used in this study is shown in Table 1.

2.10. Western Blot. Protein from right lower lung tissue or cells was extracted according to our previous research [30]. A BCA Protein Assay Kit (Thermo Fisher Scientific, USA) was used to quantify protein concentrations. SDS-PAGE gel electrophoresis was performed, and the protein was transferred from the gel to polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% BSA or skim milk. The membranes were probed with primary antibody against sEH (1:2000; Abcam), COX-2 (1:1000; Servicebio, Wuhan, China), Collagen I (1:1000; CST), E-cadherin (1:1000; CST), α-SMA (1:2000; SAB, College Park, MA, USA), Smad2 (1:1000; Abcam), Smad3 (1:1000; Abcam), p-Smad2 (1:1000; Abcam), p-Smad3 (1:1000; Abcam), Nrf2 (1:2000; CST), HO-1 (1:1000; Abcam), α-Tubulin (1:5000; Servicebio), β-Tubulin (1:5000; Proteintech, Rosemont, IL, USA), or GAPDH (1:2000; Servicebio). The primary antibody was incubated overnight. Horseradish peroxidase-conjugated secondary antibodies (1:5000; CST) at room temperature for 1 h and enhanced chemiluminescence (Millipore, USA) were applied to detect protein content. Images were captured on the Chemidoc XRS (Bio-Rad) instrument. The bands were quantified using image laboratory analyzer software (Bio-Rad).
2.11. Statistical Analyses. All data were presented as means ± standard deviation. Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA). Multiple group comparisons were made using a one-way analysis of variance. Tukey’s test was used as a post hoc test to make pairwise comparisons. Differences between the two groups were determined by an unpaired t-test. All experiments were independently repeated three times. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. PTUPB Reduces PF in Mice Induced by BLM. In this study, a COX-2/sEH dual inhibitor PTUPB (5 mg/kg, s.c. once a day) was employed on the 7th day after BLM administration. HE and Masson staining results showed that PTUPB (1 \( \mu \)M) inhibited the migratory ability of the A549 cells under the stimulation of TGF-\( \beta \)1 (10 ng/mL) ((a–b) \( n = 3 \), bar \( =500 \) px). PTUPB treatment did not affect the proliferation of A549 under low-serum conditions ((c) \( n = 5 \)). The data shown are from a representative experiment with biological triplicates. Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pairwise comparisons. \( * P < 0.05 \) and \( ** P < 0.01 \).

2.11. Statistical Analyses. All data were presented as means ± standard deviation. Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA). Multiple group comparisons were made using a one-way analysis of variance. Tukey’s test was used as a post hoc test to make pairwise comparisons. Differences between the two groups were determined by an unpaired t-test. All experiments were independently repeated three times. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. PTUPB Reduces PF in Mice Induced by BLM. In this study, a COX-2/sEH dual inhibitor PTUPB (5 mg/kg, s.c. once a day) was employed on the 7th day after BLM administration. HE and Masson staining results showed that PTUPB treatment for 14 days also significantly reduced BLM-induced lung histological changes and collagen deposition in the lungs (Figure 1(a)). PTUPB significantly decreased Collagen I protein (Figures 1(b) and 1(c)) and the expression of tissue inhibitors of metalloproteinase 1 (Timp1) mRNA (Figure 1(d)). At the same time, we found that PTUPB significantly reduced \( \alpha \)-SMA expression and restored E-cadherin expression in the lungs (Figures 1(e)–1(g)). These results suggest that the reduction of PF by PTUPB is related to the reduction of EMT.

3.2. COX-2 and sEH Expression Are Increased in TGF-\( \beta \)1-Treated AECs. The protein expressions of COX-2 and sEH were detected in TGF-\( \beta \)1-treated A549 and MLE-12 cells.
Figure 5: Prophylactic treatment of PTUPB inhibits the collagen synthesis induced by TGF-β1 in AECs. Cells were treated with TGF-β1 (10 ng/mL) for 24 h present or absent the pretreatment of PTUPB (1 μM) for 1 h. The mRNA expressions of COL1A1 (a) and FN (b) in A549 cells were detected by real-time PCR \((n=3)\). The protein expressions of Collagen I in A549 cells (c–d) and MLE-12 cells (e–f) were measured by western blotting after TGF-β1 stimulation for 48 h \((n=3)\). The data shown are from a representative experiment with biological triplicates. Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pairwise comparisons. \(*P < 0.05, **P < 0.01, and ***P < 0.001.\)
Figure 6: Continued.
Figure 6: Continued.
We found that both COX-2 and sEH protein levels were increased in TGF-β1-treated A549 (Figures 2(a)–2(c)) and MLE-12 cells (Figures 2(d)–2(f)), indicating that dysregulation of ARA metabolism participates in the development of EMT. These results suggest an important role of COX-2 and sEH dysregulation in the development of EMT.

3.3. Prophylactic Treatment of PTUPB Suppresses the TGF-β1-Induced EMT in AECs. Then, we wondered whether PTUPB suppressed the EMT induced by TGF-β1 in vitro. We observed that PTUPB alone did not affect the EMT of A549 cells (Figure S1). Further, we found that the treatment with TGF-β1 (10 ng/mL) for 12 h significantly increased the mRNA expression of actin alpha 2 (ACTA2) (encoding α-SMA) and Vimentin, indicating the occurrence of EMT, which was effectively suppressed by the pretreatment with PTUPB in A549 cells (Figures 3(a) and 3(b)). We found that PTUPB (1 μM) was the most effective inhibition concentration. In addition, western blotting results showed that the pretreatment with PTUPB (1 μM) reduced α-SMA protein expression and restored E-cadherin protein expression induced by TGF-β1 (10 ng/mL) (Figures 3(c)–3(h)). Collectively, these results provide strong evidence that PTUPB directly suppresses the EMT induced by TGF-β1 in AECs.

3.4. Prophylactic Treatment of PTUPB Inhibits the Migration Induced by TGF-β1 in A549 Cells. We further investigated the effect of PTUPB on TGF-β1-induced cell migration with the scratch wound-healing assay. The results showed that TGF-β1 treatment (10 ng/mL) for 48 h significantly promoted the migration of A549 cells. PTUPB could significantly reduce this effect (Figures 4(a) and 4(b)). In order to confirm that PTUPB inhibits cell migration but not cell proliferation, we further evaluated proliferation with CCK-8. Results showed that this effect did not attribute to the alteration of cell proliferation (Figure 4(c)). Taken together, these results indicate that PTUPB suppresses cell migration by inhibiting EMT in AECs.

3.5. Prophylactic Treatment of PTUPB Inhibits the Collagen Synthesis Induced by TGF-β1 in AECs. The collagen synthesis can directly reflect the severity of PF. We found that the gene expression of COL1A1 and fibronectin (FN) was significantly increased in A549 cells stimulated by TGF-β1, which was effectively suppressed by the pretreatment with PTUPB (Figures 5(a) and 5(b)). TGF-β1 treatment also induced the increase of protein expression of Collagen I in A549 cells and MLE-12 cells (Figures 5(c)–5(f)). Pretreatment with PTUPB restored these changes induced by TGF-β1. Altogether, these results indicate that PTUPB inhibits the TGF-β1-induced collagen synthesis in AECs.

3.6. Prophylactic Treatment of PTUPB Disrupts the TGF-β1-Smad2/3 Signaling Pathway in AECs. To elucidate the mechanism of PTUPB on EMT, we focused on the downstream signaling pathways of TGF-β1, including Smad, MAPK, and PI3K signaling pathways. We found that PTUPB had no significant effect on MAPK and PI3K signaling pathways after TGF-β1 activation (Figure S2). However, after PTUPB pretreatment, TGF-β1-induced phosphorylation of Smad2 and Smad3 in A549 cells was significantly reduced.
Figure 7: Continued.
Meanwhile, PTUPB was also observed to reduce the phosphorylation of Smad3 in MLE12 cells induced by TGF-β1 (Figures 6(d)–6(f)). At this time, the total protein of Smad2/3 in MLE12 cells and A549 cells did not change (Figure S3). Furthermore, immunofluorescence was used to observe that PTUPB reduced nuclear translocation of Smad2 and Smad3 in TGF-β1-stimulated MLE12 cells (Figure 6(g)). Then, we found that treatment with PTUPB suppressed the gene expression of the downstream targets of TGF-β1-Smad2/3 signaling, including ZEB1 and SNAIL1 (Figures 6(h) and 6(i)). These data indicate that PTUPB blocks the TGF-β1 signaling pathway through the inhibition of TGF-β1-Smad2/3 activation in AECs.

3.7. Prophylactic Treatment of PTUPB Restores Nrf2-Dependent Antioxidant Pathways in TGF-β1-Induced AECs. TGF-β1-induced down-regulation of Nrf2 protein expression and nuclear translocation in MLE12 cells and PTUPB could restore Nrf2 protein expression and nuclear translocation (Figures 7(a), 7(b), and 7(d)). Meanwhile, PTUPB up-regulated HO-1 protein expression downstream of Nrf2 (Figures 7(a) and 7(c)). Activation of Nrf2 is beneficial to ROS elimination. As expected, TGF-β1 increased ROS in MLE12 cells, and PTUPB decreased ROS content (Figure 7(d)). These results suggest that PTUPB could enhance the Nrf2 signaling pathway in AECs.

3.8. Inhibition of Nrf2 Attenuates PTUPB Regulation of TGF-β1/Smad Signaling. In MLE12 cells, inhibition of EMT by PTUPB was eliminated by blocking the Nrf2-HO-1 signaling pathway (Figures 8(a)–8(c)). PTUPB-mediated nuclear translocations of Smad2 and Smad3 were also reduced with Nrf2 inhibition (Figure 8(h)). Similarly, PTUPB-inhibited transcription of Smad2/3-downstream genes was also abolished (Figures 8(f) and 8(g)). These results suggest that
Figure 8: Continued.
Figure 8: Inhibition of Nrf2 attenuates PTUPB regulation of TGF-β1/Smad signaling. Cells were treated with PTUPB (1 μM) and ML385 (5 μM) for 1 h before the treatment with TGF-β1 (10 ng/mL). The protein expressions of Nrf2, HO-1, E-cadherin, and α-SMA in MLE12 cells (a-e) after TGF-β1 stimulation for 48 h were measured by western blotting (n = 3). Twelve hours after the TGF-β1 administration, the mRNA expressions of Zeb1 and Snail1 in MLE12 cells were detected by real-time PCR ((f-g) n = 3). Forty-eight hours after the TGF-β1 administration, the fluorescence intensity of Smad2 and Smad3 was detected by immunofluorescence ((h) bar = 50 μm). The data shown are from a representative experiment with biological triplicates. Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pairwise comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001.
activation of Nrf2 plays an important role in the regulatory effects of PTUPB on the TGF-β1/Smad axis.

4. Discussion

The transition of AECs into mesenchymal cells has been reported to cause and/or aggravate PF [6]. In this study, the direct effects of PTUPB on the TGF-β1-induced EMT were investigated. We found that PTUPB restored the phenotype changes, reduced the migration ability, and inhibited the collagen synthesis of TGF-β1-stimulated AECs by disrupting the TGF-β1-Smad2/3 pathway. We demonstrate for the first time that PTUPB blocks TGF-β1-induced EMT in AECs by inhibiting the TGF-β1-Smad2/3 signaling pathway. We found that PTUPB restored phenotypic changes, reduced migration ability, and inhibited collagen synthesis of TGF-β1-stimulated AECs. We demonstrated for the first time that PTUPB blocks EMT of AECs by up-regulating Nrf2 and inhibiting the TGF-β1-Smad2/3 signaling pathway.

ARA is one of the most abundant polyunsaturated fatty acids in the body [39]. ARA is involved in a variety of biological processes, such as angiogenesis, cell migration, and apoptosis [40]. It has been found that inhibiting sEH could increase endogenous EETs content and reduce the EMT process [29, 41]. 14,15-EET and its synthetic analog EET-A could decrease the expression of the EMT inducer factors, ZEB1 and Snail1, prevent the decrease of E-cadherin, and reduce the expression of mesenchymal/myofibroblast markers in the UUO model [29]. However, another ARA pathway, COX-2 metabolism, promotes EMT. COX-2 inhibitor-induced EMT reversal with restored E-cadherin expression has been observed in several cancer cells [42, 43]. The COX-2 metabolite PGJ2 induces EMT by up-regulating the expression of snails [44]. It can be seen that different metabolites of ARA play different roles in the process of EMT. We found that the protein expression of sEH and COX-2 increased significantly during the TGF-β1-induced EMT process, manifested by the CYP/COX-2 metabolism disorder in ARA.

Studies have found a common phenomenon in the three metabolic pathways of ARA: inhibition of any one of these pathways may shunt ARA to the other pathway, thereby reducing efficacy and causing adverse reactions [45–47]. For example, NSAIDs may have anti-inflammatory effects by inhibiting COX, but their side effects may increase the risk of stroke and kidney failure [48]. At the same time, selective inhibition of COX-2 reduces the levels of endothelin PGI2 and the platelet aggregator TXA2, which increases the risk of cardiovascular disease [46]. Therefore, the development of bimolecular inhibitors targeting ARA metabolism has become increasingly important. It has long been found that drugs targeting a single molecule can produce other toxicity and drug resistance, while drugs targeting multiple molecules are less likely to develop resistance and have better therapeutic effects [49]. PTUPB is a novel COX-2 and sEH dual inhibitor [31], and we demonstrated that PTUPB could suppress PF [30], acute lung injury [33], nonalcoholic fatty liver disease [34], and sepsis [35]. However, the direct effects of PTUPB on TGF-β1-induced EMT in AECs are unknown. In the present study, PTUPB significantly improved E-cadherin expression, decreased α-SMA
expression, and reduced excessive extracellular matrix deposition in BLM-treated mice. TIMPs serve an important role in controlling tissue organization and fibrosis following injury [50]. We found that PTUPB decreased the expression of Timp1 mRNA in BLM-treated PF mice lung tissue, which may be one of the reasons for decreased collagen synthesis.

Further, in vitro EMT models of MLE-12 and A549 cells were induced by exogenous TGF-β1. We found that PTUPB attenuated TGF-β1-induced the acquisition of mesenchymal markers (such as α-SMA), prevented TGF-β1-induced the loss of epithelial markers (such as E-cadherin), decreased TGF-β1-induced the enhancement of migration ability, and reduced TGF-β1-induced the accumulation of collagen synthesis. These results suggest that regulating COX-2/CYP metabolism in AECs alleviates TGF-β1-induced EMT. Our results support the hypothesis that inhibition of COX-2/sEH by PTUPB potently inhibits the progression of EMT. In short, our findings indicate that a COX-2 and sEH dual inhibitor show a pivotal therapeutic potential for EMT.

ROS plays an important role in the process of EMT, and TGF-β1-induced EMT can be inhibited by interfering with related upstream molecular events or by treating cells with antioxidants to block ROS production [51, 52]. These studies indicate that ROS production is an important signal for EMT initiation. It has been found that restoring intracellular antioxidant signaling pathways can reduce TGF-β1-induced EMT. For example, piperine enhances the Nrf2 antioxidant cascade, reduces TGF-β1-induced ROS accumulation, and eliminates EMT in AML-12 hepatocytes [14]. Our data show that PTUPB restored Nrf2 protein expression and nuclear translocation in TGF-β1-stimulated MLE12 cells, while reducing TGF-β1-induced intracellular ROS levels. In addition, we unveiled that inhibition of Nrf2 abrogated the protective activity of PTUPB against TGF-β1. Thus, it is reasonable to speculate that targeted activation of Nrf2 is a pivotal contributor to the lung-protective activity of PTUPB.

TGF-β1-activated Smads play an important role in the process of EMT [53]. The combination of activated Smad2 or Smad3 and Smad4 can transcriptionally regulate EMT, while blocking the expression of Smad2 or Smad3 can reduce TGF-β1-induced EMT [54]. TGF-β1 activates TβRI by acting on the receptor complex and directly phosphorylates the C-terminal of Smad2 and Smad3. After phosphorylation, Smad2, Smad3, and Smad4 form trimers, which are transported to the nucleus, bind to DNA-binding transcription factors, and cooperatively regulate the transcription of target genes [53]. Our study found that PTUPB significantly reduced TGF-β1-induced phosphorylation of Smad2 and Smad3 in A549. Meanwhile, PTUPB also reduced the phosphorylation level of Smad3 induced by TGF-β1 in MLE12 and tended to decrease the phosphorylation level of Smad2 induced by TGF-β1 in MLE12. From the multiple of Smad2/3 phosphorylation change, we believe that PTUPB mainly inhibited the phosphorylation level of Smad3 in AECs. It was further found that PTUPB decreased the expression of ZEB1 mRNA and SNAIL1 mRNA downstream of the TGF-β1-Smad signaling pathway. These data indicate that PTUPB could inhibit activation of the TGF-β1-Smad2/3 pathway, therefore suppressing TGF-β1-induced EMT.

Moreover, we also unveiled that in MLE12 cells, inhibition of Nrf2 crippled the regulatory effects of PTUPB on TGF-β1/Smad signaling. This finding suggests that activation of Nrf2 is an important upstream event that explains PTUPB-mediated modulation of intracellular TGF-β1/Smad pathways.

5. Conclusion

In summary, our findings demonstrate that the disorder in the COX-2/CYP metabolism of ARA plays a role in TGF-β1-induced EMT. PTUPB inhibits the activation of the TGF-β1-Smad2/3 pathway through the Nrf2 antioxidant cascade, thus inhibiting EMT in AECs (Figure 9). This study might promote the application of PTUPB in PF treatment.

Abbreviations

ACTA2: Actin alpha 2
AECs: Alveolar epithelial cells
ARA: Arachidonic acid
BLM: Bleomycin
CDH1: Cadherin1
COL1A1: Collagen type I alpha 1
COL1A3: Collagen type I alpha 3
COX: Cyclooxygenase
CYP: Cytochrome P450 oxidase
EMT: Epithelial-mesenchymal transition
EETs: Epoxyeicosatrienoic acids
FN: Fibronectin
HO-1: Heme oxygenase-1
LTs: Leukotrienes
LOX: Lipoxygenase
Nrf2: Nuclear factor erythroid 2-related factor-2
PGs: Prostaglandins
PF: Pulmonary fibrosis
ROS: Reactive oxygen species
sEH: Soluble epoxide hydrolase
TGF-β1: Transforming growth factor
TIMP1: Tissue inhibitor of metalloproteinase1
UUO: Unilateral ureteral obstruction
α-SMA: α-Smooth muscle actin
PTUPB: 4-[(5-phenyl-3-[3-[4-(trifluoromethyl)phenyl]-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonyamide
ZEB: Zinc-finger E-box binding.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional Points

Authors declare. The preprint has previously been published [55].
Ethical Approval

All animal experiments were approved by the Ethics Committee of the School of Basic Medical Science, Central South University (No. 2019-0901, Changsha, China).

Conflicts of Interest

The authors declared no conflict of interests.

Authors’ Contributions

Y.Z. and J.X.D. conceived and designed the experiments. C. Y.Z., X.X.G., and H.L.J. performed the experiments. C.Y.Z., Y.B.L., and Z.H.S. analyzed the data. Y.Z., P.C., and J.X.D. contributed reagents/materials/analysis tools. C.Y.Z. and Y. Z. wrote the paper. Y.Z. and J.X.D. critically reviewed the manuscript.

Acknowledgments

The authors would like to thank all the institutions and researchers who contributed to this study. This study was supported by the National Natural Science Foundation of China (91949110), the High School Innovation Fund of Hunan University (18K009), the Scientific and Technological Innovation Projects of Colleges and Universities in Shanxi Province (2019L0694), and the Fundamental Research Funds for the Central Universities of Central South University (2021zzts0314).

Supplementary Materials

Figure S1. Effects of different concentrations of PTUPB on mRNA expression of TIMP1, MMP9, and CDH1 in A549 cells. Figure S2. Prophylactic treatments of PTUPB have no effect on the PI3K and MAPK signaling pathways of AECs. Figure S3. Prophylactic treatment of PTUPB does not affect total Smads protein in AECs. (Supplementary Materials)

References

[1] L. Richeldi, H. R. Collard, and M. G. Jones, "Idiopathic pulmonary fibrosis," Lancet, vol. 389, no. 10082, pp. 1941–1952, 2017.
[2] S. T. Lehtonen, A. Veijola, H. Karvonen et al., "Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis," Respiratory Research, vol. 17, no. 1, 2016.
[3] A. L. Mora, M. Rojas, A. Pardo, and M. Selman, “Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease,” Nature Reviews. Drug Discovery, vol. 16, no. 11, pp. 755–772, 2017.
[4] L. Yao, F. Conforti, C. Hill et al., "Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis," Cell Death and Differentiation, vol. 26, no. 5, pp. 943–957, 2019.
[5] M. A. Nieto, R. Y. Huang, R. A. Jackson, and J. P. Thiery, "Emt: 2016," Cell, vol. 166, no. 1, pp. 21–45, 2016.
[6] L. Zhou, R. Gao, H. Hong et al., “Emodin inhibiting neutrophil elastase-induced epithelial-mesenchymal transition through Notch1 signalling in alveolar epithelial cells,” Journal of Cellular and Molecular Medicine, vol. 24, no. 20, pp. 11998–12007, 2020.
[7] J. Qu, Z. Zhang, P. Zhang et al., "Downregulation of HMGB1 is required for the protective role of Nrf2 in EMT-mediated PF," Journal of Cellular Physiology, vol. 234, no. 6, pp. 8862–8872, 2019.
[8] H. Tanjore, X. C. Xu, V. V. Polosukhin et al., “Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 7, pp. 657–665, 2009.
[9] J. Su, S. M. Morgani, C. J. David et al., "TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1," Nature, vol. 577, no. 7791, pp. 566–571, 2020.
[10] C. Huang, H. Wang, J. Pan et al., "Benzalkonium chloride induces subconjunctival fibrosis through the COX-2-modulated activation of a TGF-1/Smad3 signaling pathway," Investigative Ophthalmology & Visual Science, vol. 55, no. 12, pp. 8111–8122, 2014.
[11] M. G. Gwon, H. J. An, J. Y. Kim et al., "Anti-fibrotic effects of synthetic TGF-β1 and Smad oligodeoxynucleotide on kidney fibrosis in vivo and in vitro through inhibition of both epithelial dedifferentiation and endothelial-mesenchymal transition," The FASEB Journal, vol. 34, no. 1, pp. 333–349, 2020.
[12] A. Dendooven, D. A. Ishola Jr., T. Q. Nguyen et al., "Oxidative stress in obstructive nephropathy," International Journal of Experimental Pathology, vol. 92, no. 3, pp. 202–210, 2011.
[13] N. Kikuchi, Y. Ishii, Y. Morishima et al., "Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance," Respiratory Research, vol. 11, no. 1, p. 31, 2010.
[14] G. Shu, A. Yusuf, C. Dai, H. Sun, and X. Deng, "Piperine inhibits AML-12 hepatocyte EMET and LX-2 HSC activation and alleviates mouse liver fibrosis provoked by CCl4: roles in the activation of the Nrf2 cascade and subsequent suppression of the TGF-β1/Smad axis," Food & Function, vol. 12, no. 22, pp. 11686–11703, 2021.
[15] M. A. Aminzadeh, S. B. Nicholas, K. C. Norris, and N. D. Vaziri, "Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulointerstitial nephropathy," Nephrology, Dialysis, Transplantation, vol. 28, no. 8, pp. 2038–2045, 2013.
[16] Y. Y. Han, X. Gu, C. Y. Yang et al., “Protective effect of dimethyl itaconate against fibroblast–myofibroblast differentiation during pulmonary fibrosis by inhibiting TXNIP," Journal of Cellular Physiology, vol. 236, no. 11, pp. 7734–7744, 2021.
[17] J. Zhao, J. Shi, Y. Shan et al., "Asiaticoside inhibits TGF-β1-induced mesothelial-mesenchymal transition and oxidative stress via the Nrf2/HO-1 signaling pathway in the human peritoneal mesothelial cell line HM595V5," Cellular & Molecular Biology Letters, vol. 25, no. 1, p. 33, 2020.
[18] V. S. Hanna and E. A. A. Hafez, “Synopsis of arachidonic acid metabolism: a review," Journal of Advanced Research, vol. 11, pp. 23–32, 2018.
[19] F. Li, Y. Sun, J. Jia et al., "Silibinin attenuates TGF-β1-induced migration and invasion via EMT suppression and is associated with COX-2 downregulation in bladder transitional cell carcinoma," Oncology Reports, vol. 40, no. 6, pp. 3543–3550, 2018.
[20] M. Tsuji, S. Kawano, S. Tsuji, H. Sawaoka, M. Horii, and R. N. Dubois, "Cylooxygenase regulates angiogenesis induced by colon cancer cells," Cell, vol. 93, no. 5, pp. 705–716, 1998.
[21] M. C. LaPointe, M. Mendez, A. Leung, Z. Tao, and X. P. Yang, "Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse," American Journal of Physiology. Heart and Circulatory Physiology, vol. 286, no. 4, pp. H1416–H1424, 2004.

[22] Y. Watanabe, Y. Imanishi, H. Ozawa et al., “Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer," American Journal of Translational Research, vol. 12, no. 3, pp. 1096–1113, 2020.

[23] J. D. Imig, "Epoxides and soluble epoxide hydrolase in cardiovascular physiology," Physiological Reviews, vol. 92, no. 1, pp. 101–130, 2012.

[24] S. Zarriello, J. P. Tuazon, S. Corey et al., "Humle beginnings with big goals: small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders," Progress in Neurobiology, vol. 172, pp. 23–39, 2019.

[25] Z. He, Y. Yang, Z. Wen et al., "CYP2J2 metabolites, epoxycosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Galphai2/13," Journal of Lipid Research, vol. 58, no. 7, pp. 1338–1353, 2017.

[26] Y. Zhou, T. Liu, J. X. Duan et al., "Soluble epoxide hydrolase inhibitor attenuates lipopolysaccharide-induced acute lung injury and improves survival in mice," Shock, vol. 47, no. 5, pp. 638–645, 2017.

[27] X. Q. Luo, J. X. Duan, H. H. Yang et al., "Epoxycosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages," Journal of Cellular Physiology, vol. 235, no. 12, pp. 9910–9921, 2020.

[28] Y. Zhou, J. Yang, G. Y. Sun et al., "Soluble epoxide hydrolase inhibitor 1-trifluoromethylphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice," Cell and Tissue Research, vol. 363, no. 2, pp. 399–409, 2016.

[29] M. Skibba, M. A. Hye Khan, L. L. Kolb et al., "Epoxycosatrienoic acid analog decreases renal fibrosis by reducing epithelial-to-mesenchymal transition," Frontiers in Pharmacology, vol. 8, p. 406, 2017.

[30] C. Y. Zhang, J. X. Duan, H. H. Yang et al., "COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence," The FEBS Journal, vol. 287, no. 8, pp. 1666–1680, 2020.

[31] S. H. Hwang, K. M. Wagner, C. Morisseau et al., "Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase," Journal of Medicinal Chemistry, vol. 54, no. 8, pp. 3037–3050, 2011.

[32] G. Zhang, D. Panigrahy, S. H. Hwang et al., "Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 30, pp. 11127–11132, 2014.

[33] H. H. Yang, J. X. Duan, S. K. Liu et al., "A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation," Theranostics, vol. 10, no. 11, pp. 4749–4761, 2020.

[34] C. C. Sun, C. Y. Zhang, J. X. Duan et al., "PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice," Biochemical and Biophysical Research Communications, vol. 523, no. 4, pp. 1020–1026, 2020.

[35] Y. F. Zhang, C. C. Sun, J. X. Duan et al., "A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress," Biomedicine & Pharmacotherapy, vol. 126, article 109907, 2020.

[36] M. Shao, Z. B. Wen, H. H. Yang et al., "Exogenous angiotensin (1-7) directly inhibits epithelial-mesenchymal transformation induced by transforming growth factor-β1 in alveolar epithelial cells," Biomedicine & Pharmacotherapy, vol. 117, article 101913, 2019.

[37] W. J. Zhong, H. H. Yang, X. X. Guan et al., "Inhibition of glycolysis alleviates lipopolysaccharide-induced acute lung injury in a mouse model," Journal of Cellular Physiology, vol. 234, no. 4, pp. 4641–4654, 2019.

[38] W. J. Zhong, J. X. Duan, T. Liu et al., "Activation of NLRP3 inflammasome up-regulates TREM-1 expression in murine macrophages via HMGBl and IL-18," International Immunopharmacology, vol. 89, article 107045, Part A, 2020.

[39] S. A. Martin, A. R. Brash, and R. C. Murphy, "The discovery and early structural studies of arachidonic acid," Journal of Lipid Research, vol. 57, no. 7, pp. 1126–1132, 2016.

[40] R. Martinez-Orozco, N. Navarro-Tito, A. Soto-Guzman, L. Castro-Sanchez, and E. Perez Salazar, "Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A," European Journal of Cell Biology, vol. 89, no. 6, pp. 476–488, 2010.

[41] S. H. Yang, Y. C. Kim, J. N. An et al., "Active maintenance of endothelial cells prevents kidney fibrosis," Kidney Research and Clinical Practice, vol. 36, no. 4, pp. 329–341, 2017.

[42] C. Bocca, M. Ilevollela, R. Autelli et al., "Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness," Expert Opinion on Therapeutic Targets, vol. 18, no. 2, pp. 121–135, 2014.

[43] M. A. St John, M. Dohadwala, J. Luo et al., "Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma," Clinical Cancer Research, vol. 15, no. 19, pp. 6018–6027, 2009.

[44] J. Choi, Y. J. Suh, D. H. Kim, H. K. Na, and Y. J. Surh, "15-Deoxy-delta(12,14)-prostaglandin J2 induces epithelial-to-mesenchymal transition in human breast cancer cells and promotes fibroblast activation," Journal of Cancer Prevention, vol. 25, no. 3, pp. 152–163, 2020.

[45] Y. Liu, H. Tang, X. Liu et al., "Frontline science: reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis," Journal of Leukocyte Biology, vol. 105, no. 1, pp. 201–212, 2019.

[46] S. L. Manju, K. R. Ezhiraj, and G. Elias, "Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: a structure-based approach," European Journal of Pharmacological Sciences, vol. 121, pp. 356–381, 2018.

[47] H. S. Kim, S. K. Kim, and K. W. Kang, "Differential effects of sEH inhibitors on the proliferation and migration of vascular smooth muscle cells," International Journal of Molecular Sciences, vol. 18, no. 12, p. 2683, 2017.

[48] C. Cooper, R. Chapurlat, N. Al-Daghri et al., "Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say?," Drugs & Aging, vol. 36, Supplement 1, pp. 15–24, 2019.
[49] G. R. Zimmermann, J. Lehar, and C. T. Keith, “Multi-target therapeutics: when the whole is greater than the sum of the parts,” Drug Discovery Today, vol. 12, no. 1-2, pp. 34–42, 2007.

[50] W. L. Zuo, J. M. Zhao, J. X. Huang et al., “Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis,” Biomedical Reports, vol. 6, no. 2, pp. 201–205, 2017.

[51] M. Ma, F. Shi, R. Zhai et al., “TGF-β promote epithelial-mesenchymal transition via NF-κB/NOX4/ROS signal pathway in lung cancer cells,” Molecular Biology Reports, vol. 48, no. 3, pp. 2365–2375, 2021.

[52] X. Su, Y. Yang, C. Guo et al., “NOX4-derived ROS mediates TGF-beta1-induced metabolic reprogramming during epithelial-mesenchymal Transition through the PI3K/AKT/HIF-1alpha pathway in glioblastoma,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 5549047, 30 pages, 2021.

[53] J. Xu, S. Lamouille, and R. Derynck, “TGF-β-induced epithelial to mesenchymal transition,” Cell Research, vol. 19, no. 2, pp. 156–172, 2009.

[54] U. Valcourt, M. Kowanetz, H. Niimi, C. H. Heldin, and A. Moustakas, “TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition,” Molecular Biology of the Cell, vol. 16, no. 4, pp. 1987–2002, 2005.

[55] Z. Chen-Yu, G. Xin-Xin, S. Zhuo-Hui et al., “COX-2/sEH dual inhibitor PTUPB attenuates epithelial-mesenchymal transformation of alveolar epithelial cells via Nrf2-mediated inhibition of TGF-β1/Smad signaling,” Research Square, 2021.